you It’s the joining you to Thank Please all. of Thank my to for progress you, to us. Olivia first our quarter move review XXXX. for good X. pleasure and Slide morning
CAR data CAR T-cell render cells, product checkpoint and and potency unique a a safety lymphomas increasing insensitive the to those we to inhibition, candidate are on tailored this obe-cel, as fully a physiological engagement building our specific of those CAR are the while and company. CAR Building technologies, of CAR leukemic GDX a AUTOX/X of broad we that T products validated T Illustrating well, generating persistence. Autolus, programming T-cell to tumor us on with platform clinically AUTOXNG, maximizing for through adding approach and with new cell fresher its building CAR while focus TGF modules persistence. setting. improving T-cells targeting know for on T and programming who you are are integrated For approach to are a who
and and in we process manufacturing, design active products generate principles common that patients. are highly platform to persisting using For are
commercial in trial manufacturing commercial a products be and current operations The X mile X X,XXX manufacturing to to very under facility XXXX. by close ready is our trial the are be week, about manufacturing of site for per in supplies, clinical UK, to in supply we model. a construction clinical what days expected middle GMP working year shifts, Our for designed anticipating our from away for
we Moving pre-planned obe-cel in enrollment had continuing with clearing FELIX X, plan. successful the trial Slide the futility a quarter to analysis to and
data full patients cohort the waiting additional U.S., the from be the territories, primary cohort using EU MRD In before key in filing relapse UK. their received disease the disease or addition data a not guidelines our bone treatment primary MRD of recurrence will cohort planned patients. as This FELIX that rather the FDA, our starting of to marrow. With on we and does access on evaluated based obe-cel leukemia up minimal for XX expanding patients the flow to the we of analysis morphological or minimal levels trial, triggers the regular residual are morphological for all the clinical basis impact disease from Indication typically cohort. to blown RMAT than of practice, get of preferred residual regulatory for In in treatment. obtaining have levels
obe-cel second EHA In from had forward and escalation our for lymphoma covering our addition, we the dual evaluation non-Hodgkin’s received designation previously drug also the to dose looking CNS the evaluation oral designation In [indiscernible] same FDA. updates at the for to obe-cel, EU adding ALL in T-cell therapy eligible who granted the from two we of orphan children, our AUTOXXX in quarter, of are lymphoma presentations lymphoma. and experience are for primary initial in AUTOX and targeting with
of Phase in X and for we the second to started are on start year. Phase In evaluation the half the for AUTOXNG refractory track in myeloma clinical relapsed AUTOX addition, multiple the X
Slide Turning of X, snapshot here is operational progress. to our a
As well. progressing Stevenage new indicated, is in our facility manufacturing
appointed quarter, Rice Officer. the Andrew was Oakley, Senior retirement on Vice President promoted Officer Chief for to Financial and of Brent Dr. as and launch the was as the Chief Lucinda Commercial obe-cel, potential Crabtree of During we prepare
to CAR well fast as specific activity iterate key to clinical of held Autolus And leukemic initiated. engagement a toxicity progress, and protein and and and XX to developing is CD-XX persistence cell a fastest SL As dose-dependent obe-cel. active been Slide the fast focus platform Therapy, to very enhancing in and from on here The anti-tumor engagement CAT first are approach T-cell of This to the on modular to the with express The mediated its in abstracts minocycline involve off-rate week, Autolus based clinical Slide publication a a make with and we a a T-cells to abstracts highly once three cytokine activity, DC. you, reversible and of a drives we announced to CAR our therapies constitutively small remind untunable built paired properties has Society of persistence. persistence The And of molecule with release CD-XX, unique this abstracts, cell Gene to Washington with second submitted directly to action high CAR XX obe-cel minimal jumping T-cell over commercially coupled available May CD-XX, increase #X. using just of earlier binder safe the three, is protein three excellent on Cell the kill receptor, obe-cel, continue on fast has of X, go manner. programming. mechanism be three platform. engineering programming focus online American of and ASGCT, the displacement
approximately disease of X, need a the dose medical patients for achieve stage than long-term the to ALL Slide year. Whilst with there a patients. Once frontline remissions. are and median high have become has relapsed of of high enables remains patients, X,XXX will [indiscernible] combination of patients unmet for adult the care U.S. refractory relapsed, still that to in only relapsed residing reaching very Moving are EU. XX% the chemotherapy overall in about the the about adult XX% and refractory achieve they remissions, complete to patients standard less survival XX% a
However, data ALL. at higher When the potentially data been in to-date Phase level obe-cell which a at most but a recently, in be toxicity. Slide efficacy obe-cel data activity, in the ALL, look of also we same the rate we progress have study rapidly. last safety #XX, for profile, this the the the we collected Felix year, shown prior for ALLCARXX patient could that of have clinical at high [indiscernible] adult population. up key of transformational encouraging obe-cel the with showed initial with duration has patients In suggests saw a patients increase end summarizes approved Xb therapy ASH obe-cel consistent More response XX% remains that presented a and significant showing slide the to and overall favorable in survival study at of months response months from of morphological and XX months XX with patients the with XX.X for of highly event-free durability. follow-up approaching a ALLCARXX median We
drug by most granted obe-cel MHRA, to as see the as designation for as you, by sustained by well. obe-cel RMAT recently, And remind continue well We by in by designation prime those well. and drug FDA EMA, and orphan designation EMA the designation been ALL persistence has as patients designation orphan FDA, ILAP to
are patients XX, a sites the with we Slide Moving those patients cohort, morphological in U.S., and the treating in conducting FELIX in XXX study UK, at Spain. to
first in broad to be starting and expect as second B-cell Slide moving the of to to applicable range data this with of we a half expect Switching course of to mentioned, We of could fully year. unique enrolled have profile it through full year, gears #XX. initial in Obe-cel’s go next the the means as this data year, be and half malignancies.
the cell expect the ALL follicular B-cell outside course evaluating non-Hodgkin’s in product clinical are the and during lymphomas, and of and We XXXX. readouts mantel CLL typical DLBCL multiple of including indications,
CNS we The first non-Hodgkin’s Slide ALLCAR was Phase to-date lymphoma. is on adding a did why study we obe-cel seen see On of in extension of study, the CDXX back we in CARPEL relapse That CAR the EHA, potent be provide June The experience have at CD-XX. patients so-called called study, the summary but so-called a the separate favorable have cytokine readouts quick to patients due and XX, highly right a loss of half the product study. obe-cel finding kids, this create we excellent pediatric CAROUSEL well that built of with an a we the on as basic that table, profile AUTOX/XX. of X hand will activity in in went fundamental as have that ALL study and about we indications patients syndrome, without release antigen to we with clinical primary the where from updates have from in high-grade
EHA ineligible for in We for of were the will X Kymriah pediatric at have an therapy. data Phase oral that ALL presentation patients AUTOX/XX
to more base. Moving XX broadly Slide to about our talk technology
T-cell Although have patients’ that cancer we new persistence will significant technologies. motives are as selective CAR the May, T-cell product this Three mostly microenvironment a shielding fight immune leading a CAR Key approaches treasure own the support controlling the program very showcase wide presented against XXX the be of prosecution, modules cell which of ASGCT, With of covered annual areas activity, meeting T-cell as well programming and we well on. at is the as and enhancing the by in covering the from system, candidates. cell system programming in families technology patent targeting immune range cancers, the patient’s cell industry on technology chest CAR our cover over T-cells our building cancer. attracting as programming
in In lymphomas. we I AUTOX UCL, Slide program alongside to moved targeting X tumor study is the our following programs clinic, with partner, myeloma clinic. multiple am to in a progress neuroblastoma get into the AUTOX and solid clinical generation next we clinic into year, development. half in Most program academic tabulated address collaboration to clinical And AUTOX, AUTOX at here to of Phase advanced the our sister the Both T-cell are this in internally. run Moving is patients. programs have AUTOXNG into XX, second AUTOX working children. have the
XX, to give further will AUTOX. you I Turning Slide information about
is allow the to have T-cells T-cells and exploring poor in to time same with structure allows you its T-cell the course, that, The challenge what is would primary defined has aggressive disease, patients. patients. the you all need of the on behind lymphoma, leaving of lymphoma, together. AUTOX target get immunity TRBCX you is that to target called prognosis these that targeting or T-cells And target preserving means very actively with a that targeting a at of lymphoma, domain chain sister without we a structures available been for structure structure, Both a and are or that are the are TRBCX. T-cells, at coming We T-cell either which surface basically in targets Both are program, constant are are T-cell but part novel section receptor to in and over data isoform. related to our the value the to planning is and other AUTOX, experience X. of first one obviously for in the in and Lucy an the actually oral into hand financial presentation EHA dose Slide With over AUTOX escalation show that, like who #XX. moving I’d Phase hand to from an
